ESTRO 2025 - Abstract Book

S778

Clinical - Gynaecology

ESTRO 2025

Conclusion: The prevalence of sarcopenia is high in women treated with radiotherapy for gynecological cancer. A notable increase was observed during the course of treatment, reaching its highest prevalence at the three-month follow-up. Sarcopenia may be underestimated when assessed by BIA or weight loss alone. The BIA does not appear to be a reliable bedside measurement for sarcopenia.

Keywords: sarcopenia, longitudinal, pelvic radiotherapy

References: 1. Lin WL, Nguyen TH, Lin CY, Wu LM, Huang WT, Guo HR. Association between sarcopenia and survival in patients with gynecologic cancer: A systematic review and meta-analysis. Front Oncol . 2022;12:1037796. doi:10.3389/fonc.2022.1037796 2. Obermair A, Simunovic M, Isenring L, Janda M. Nutrition interventions in patients with gynecological cancers requiring surgery. Gynecol Oncol . Apr 2017;145(1):192-199. doi:10.1016/j.ygyno.2017.01.028 3. Branco MG, Mateus C, Capelas ML, et al. Bioelectrical Impedance Analysis (BIA) for the Assessment of Body Composition in Oncology: A Scoping Review. Nutrients . Nov 15 2023;15(22)doi:10.3390/nu15224792

346

Mini-Oral DE-escalated Conformal Radiation Expedited Sequentially with Chemotherapy for locally advanced ENDOmetrial cancer (DECRESCENDO) - NCT04386993 Joshua Philip Schiff 1,2 , Silpa Raju 3 , Tyler R McKinnish 4 , Julia Huecker 5 , Alexander J Lin 6 , Casey Hatscher 1 , David Mutch 4 , Andrea R Hagemann 4 , Dineo Khabele 4 , Lindsay M Kuroki 4 , Leslie S Massad 4 , Carolyn K McCourt 4 , Premal H Thaker 4 , Matthew A Powell 4 , Julie Schwarz 1 , Stephanie T Markovina 1 , Jessika A Contreras 1